Aurion Biotech appoint Donald Munoz as chief financial officer
Donald Munoz has over 30 years of health care experience as a chief financial officer and an investment banker.
(Image credit: AdobeStock/peshkova)
Aurion Biotech, Inc. has appointed Donald Munoz as chief financial officer (CFO).
Greg Kunst, Aurion’s CEO, commented on this news in the company’s press release1, saying, “We are delighted to welcome Don to our executive team. Don’s track record of strategic and operational financial leadership, coupled with his extensive experience as a healthcare investment banker, make him an ideal addition to Aurion.”
According to the company1, Donald Munoz has over 30 years of health care experience as a chief financial officer and an investment banker. Prior to joining Aurion, Don spent more than nine years as chief financial officer of NuCana plc, a publicly traded biotechnology company developing oncology therapeutics. At NuCana, Don oversaw financial management, investor relations, Securities and Exchange Commission reporting, audit, tax, and financial planning and analysis. Don also led NuCana’s $114 million Nasdaq initial public offering and $80 million follow-on offering. Before NuCana, Don was the chief financial officer of NOXXON Pharma N.V., a venture-backed biotechnology company.
Previously, Don spent 20 years as a healthcare investment banker leading the medical technology franchises for Cowen & Company, LLC, Leerink Partners LLC and Deutsche Bank AG, which he joined through its acquisition of Alex. Brown & Sons. Don has completed more than 100 financing and strategic advisory transactions throughout his career. Don holds an MBA from Columbia Business School and a BA from Dartmouth College.1
This news follows December 2024 announcement that of positive six-month top-line data from its CLARA Phase 1/2 clinical trial in the United States and Canada.1
